DP
MNPR icon

Diadema Partners’s Monopar Therapeutics MNPR Stock Holding History

Diadema Partners’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$89.3K Buy
+1,630
New +$98.5K 0.02% 131

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Diadema Partners's MNPR Position: Q1 2026 in Review

Diadema Partners opened a new position in Monopar Therapeutics (MNPR) in Q1 2026: 1,630 shares worth $89.3K. The stake represents 0.02% of the portfolio and ranks #131 among its holdings.

82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • Diadema Partners held 1,630 shares of Monopar Therapeutics worth $89.3K as of Q1 2026.
  • Monopar Therapeutics was a new Diadema Partners position in Q1 2026.
  • Monopar Therapeutics made up 0.02% of Diadema Partners's portfolio in Q1 2026, its #131 holding.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.